Urogen Pharma (DE:UR8)
NASDAQ:UR8
Total Valuation
Urogen Pharma has a market cap or net worth of €1.47B. The enterprise value is €1.68B.
Market Cap€1.47B
Enterprise Value€1.68B
Share Statistics
Urogen Pharma has 48,721,703 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,721,703
Owned by Insiders1.92%
Owned by Institutions52.66%
Financial Efficiency
Urogen Pharma’s return on equity (ROE) is 1.46 and return on invested capital (ROIC) is -81.06%.
Return on Equity (ROE)1.46
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-81.06%
Return on Capital Employed (ROCE)-0.81
Revenue Per Employee377.28K
Profits Per Employee-527.47K
Employee Count291
Asset Turnover0.55
Inventory Turnover0.76
Valuation Ratios
The current PE Ratio of Urogen Pharma is ―. Urogen Pharma’s PEG ratio is -0.94.
PE Ratio―
PS Ratio10.26
PB Ratio-10.68
Price to Fair Value-10.68
Price to FCF-6.92
Price to Operating Cash Flow-10.41
PEG Ratio-0.94
Income Statement
In the last 12 months, Urogen Pharma had revenue of 109.79M and earned -153.49M in profits. Earnings per share was -3.19.
Revenue109.79M
Gross Profit97.34M
Operating Income-124.86M
Pretax Income-153.42M
Net Income-153.49M
EBITDA-135.66M
Earnings Per Share (EPS)-3.19
Cash Flow
In the last 12 months, operating cash flow was -165.74M and capital expenditures -299.00K, giving a free cash flow of -166.03M billion.
Operating Cash Flow-165.74M
Free Cash Flow-166.03M
Free Cash Flow per Share-3.41
Dividends & Yields
Urogen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.65
52-Week Price Change169.20%
50-Day Moving Average23.38
200-Day Moving Average18.79
Relative Strength Index (RSI)76.43
Average Volume (3m)4.00
Important Dates
Urogen Pharma upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Urogen Pharma as a current ratio of 4.01, with Debt / Equity ratio of -158.62%
Current Ratio4.01
Quick Ratio3.65
Debt to Market Cap0.11
Net Debt to EBITDA-0.13
Interest Coverage Ratio-3.69
Taxes
In the past 12 months, Urogen Pharma has paid 78.00K in taxes.
Income Tax78.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Urogen Pharma EV to EBITDA ratio is -8.44, with an EV/FCF ratio of -7.03.
EV to Sales10.42
EV to EBITDA-8.44
EV to Free Cash Flow-7.03
EV to Operating Cash Flow-7.05
Balance Sheet
Urogen Pharma has €141.60M in cash and marketable securities with €197.09M in debt, giving a net cash position of -€55.49M billion.
Cash & Marketable Securities€141.60M
Total Debt€197.09M
Net Cash-€55.49M
Net Cash Per Share-€1.14
Tangible Book Value Per Share-€2.19
Margins
Gross margin is 89.85%, with operating margin of -113.73%, and net profit margin of -139.81%.
Gross Margin89.85%
Operating Margin-113.73%
Pretax Margin-139.74%
Net Profit Margin-139.81%
EBITDA Margin-123.57%
EBIT Margin-125.76%
Analyst Forecast
The average price target for Urogen Pharma is €32.05, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€32.05
Price Target Upside80.66% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast35.98%
EPS Growth Forecast20.45%